AR003921A1 - Combinacion activa farmaceutica - Google Patents

Combinacion activa farmaceutica

Info

Publication number
AR003921A1
AR003921A1 ARP960101224A AR10122496A AR003921A1 AR 003921 A1 AR003921 A1 AR 003921A1 AR P960101224 A ARP960101224 A AR P960101224A AR 10122496 A AR10122496 A AR 10122496A AR 003921 A1 AR003921 A1 AR 003921A1
Authority
AR
Argentina
Prior art keywords
drug
benzodiazepine
melatonin
patient
addiction
Prior art date
Application number
ARP960101224A
Other languages
English (en)
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of AR003921A1 publication Critical patent/AR003921A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La melatonina se emplea para la manufactura de un medicamento para tratar la adicción a benzodiacepina en un adicto a multidrogas o a un paciente quetiene síntomas de dependencia, tolerancia o adicción a una droga de benzodiacepina, op ara tratar un paciente al cual se le ha diagnosticadoclínicamente que sufre de un estado que es susceptible de ser aliviado mediante la administración de una droga de benzodiacepina mientras se evitasimultáneamente que se produzcan en el pacientesín tomas de dependencia, tolerancia o adicción a dicha droga. Dicho medicamento contiene por lo menosuna cantidad efectiva de melatonina para cualquiera de dichos tratamientos, siendo adaptada dicha cantidad para una razón diaria deadministr ación dentrodel rango de 0,01-100 mg, con lo que, cuando dicho medicamento es para el tratamiento de un paciente al que se le ha diagnosticado clínicamente de tenerun estado susceptible al alivio mediante la administración de unadroga de benzodiacepina, entonces dicho medicamento es una formulación farmacéuticade liberación sostenida que contiene no más de 5 mg de melatonina. Formulaciones farmacéuticas para los propósitos antes mencionados quecomprenden por lomenos un diluyentes, portador o coadyuvante y como ingredientes activos, una droga de benzodiacepina y melatonina; y unprocedimiento para la preparación de dichas formulaciones farmacéuticas.
ARP960101224A 1995-02-01 1996-01-30 Combinacion activa farmaceutica AR003921A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP95303853A EP0724878B1 (en) 1995-02-01 1995-06-06 Use of melatonin for treating patients suffering from drug dependencies

Publications (1)

Publication Number Publication Date
AR003921A1 true AR003921A1 (es) 1998-09-30

Family

ID=23505399

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101224A AR003921A1 (es) 1995-02-01 1996-01-30 Combinacion activa farmaceutica

Country Status (13)

Country Link
US (3) US6469044B1 (es)
EP (1) EP0724878B1 (es)
KR (1) KR100425045B1 (es)
AR (1) AR003921A1 (es)
DE (1) DE69512760T2 (es)
ES (1) ES2139842T3 (es)
HK (1) HK1001218A1 (es)
IL (1) IL114296A (es)
LT (1) LT4339B (es)
RO (1) RO116771B1 (es)
RU (1) RU2182001C2 (es)
UA (1) UA63878C2 (es)
ZA (1) ZA96548B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469044B1 (en) * 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
IL130171A (en) * 1999-05-27 2004-06-01 Neurim Pharma 1991 Melatonin for use in preventing and treating tardive dyskinesia, pharmaceutical preparations containing it and its use in the manufacture of medicines
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US6998112B2 (en) * 2003-03-18 2006-02-14 Arthur Zuckerman Sleep inducing toothpaste made with natural herbs and a natural hormone
CA2556753C (en) * 2004-02-20 2014-11-25 Lifescape Biosciences Incorporated Compositions and methods for sleep regulation
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
CN103442727B (zh) 2011-02-11 2016-08-10 Zx制药有限责任公司 多微粒l-薄荷醇制剂及相关方法
RU2488388C1 (ru) 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
RS58325B1 (sr) 2013-04-23 2019-03-29 Zx Pharma Llc Enterosolventno obloženi višečestični preparat sa proteinskom sub-oblogom
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
AU2016426598C1 (en) 2016-10-31 2024-02-08 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
WO2024079125A1 (en) 2022-10-14 2024-04-18 Société des Produits Nestlé S.A. Sustained release melatonin compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
AU601736B2 (en) 1986-05-23 1990-09-20 Sanofi Sante Nutrition Animale Sa Coated veterinary implants
US4800087A (en) 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US5242941A (en) 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
DE122007000073I1 (de) * 1991-05-09 2008-01-31 Neurim Pharma 1991 Melatonin enthaltene Arzneimittel
IT1251544B (it) 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
US5449683A (en) 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
US6469044B1 (en) * 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies

Also Published As

Publication number Publication date
RO116771B1 (ro) 2001-06-29
UA63878C2 (en) 2004-02-16
DE69512760D1 (de) 1999-11-18
US6469044B1 (en) 2002-10-22
US6833383B2 (en) 2004-12-21
LT97135A (en) 1997-12-29
LT4339B (lt) 1998-05-25
IL114296A0 (en) 1995-10-31
IL114296A (en) 1999-10-28
US20030040539A1 (en) 2003-02-27
KR100425045B1 (ko) 2004-09-01
EP0724878A3 (es) 1996-08-21
RU2182001C2 (ru) 2002-05-10
HK1001218A1 (en) 1998-06-05
EP0724878A2 (en) 1996-08-07
DE69512760T2 (de) 2000-05-31
KR19980701640A (ko) 1998-06-25
ES2139842T3 (es) 2000-02-16
US20020156121A1 (en) 2002-10-24
EP0724878B1 (en) 1999-10-13
ZA96548B (en) 1996-08-14

Similar Documents

Publication Publication Date Title
AR003921A1 (es) Combinacion activa farmaceutica
EP0724885A4 (en) COMPOSITION ADMINISTERED BY NASAL AND PREPARATION CONTAINING THE SAME
US20090018151A1 (en) Topical Treatment of Peripheral diabetic complications
MX173567B (es) Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih
KR970061244A (ko) 치매 치료용 약학 조성물
RU2005131868A (ru) Фармацевтическая композиция, фармацевтическая комбинация (варианты) и способы их применения
US5798093A (en) Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions and pruritus therewith
MXPA05005781A (es) Combinacion de ibuprofeno y oxicodona para alivio de dolor agudo.
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
Tegner Severe skin pain after PUVA treatment
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
Elizan et al. Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease: experience in 26 patients receiving combined therapy for 26 months
KR100420673B1 (ko) 지연된구토반응을치료하기위한비강투여제
JPWO2008120562A1 (ja) 帯状疱疹後神経痛治療用錠剤および帯状疱疹後神経痛の治療方法
AU777508B2 (en) Methods and kits for treating vulvovaginal candidiasis with miconazole nitrate
VILKIN Comparative chemotherapeutic trial in treatment of chronic borderline patients
KR100692235B1 (ko) 안지오텐신 ⅱ 길항물질의 신규한 용도
FR2587213A1 (fr) Medicament pour le traitement de la dependance aux psychostimulants
AR006202A1 (es) Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene
WO1997044045A1 (en) Malatonin in combination with analgesics
KR20000029647A (ko) 양극성장애의치료방법
US5216019A (en) Pain killer
EP0402208A1 (fr) Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique
AR015537A1 (es) Uso de brinzolamida para la manufactura de un medicamento para tratar o prevenir edema de retina.
US3686409A (en) Combination of l-dopa and 2-imino-5-phenyl-4-oxazolidinone used to treat parkinson{40 s disease

Legal Events

Date Code Title Description
FC Refusal